---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006383"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:12:04.684601+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Record Q1 net sales of $85.6M (+16% YoY); raised 2024 guidance to $357-$365M

## Summary
- Glaucoma segment sales $67.2M (+20% YoY); Corneal Health $18.4M (+4% YoY).
- GAAP gross margin 76%; non-GAAP gross margin 83%.
- GAAP net loss per share ($0.82); non-GAAP net loss per share ($0.70) includes $11.7M IPR&D charge.
- Raised 2024 net sales guidance from $350-$360M to $357-$365M.
- Cash and investments ~$279M at quarter end.

## SEC filing metadata
- accession: 0001558370-24-006383
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000155837024006383/0001558370-24-006383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000155837024006383/gkos-20240501x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006383
- JSON: https://secwatch.observer/filing/0001558370-24-006383.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006383.txt

## Key facts
- Earnings Releases
  GLAUKOS Corp reported first quarter ended March 31, 2024 results: revenue $85.6 million, net income ($40.8 million), EPS ($0.82) per diluted share. Guidance raised.
  - Period: first quarter ended March 31, 2024
  - Revenue: $85.6 million
  - Net income: ($40.8 million)
  - EPS: ($0.82) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: ● Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. ● Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. ● Corneal Health net sales of $18.4 million in Q1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1192448/000155837024006383/0001558370-24-006383-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.